Vijay Pande, who previously managed a $4 billion healthcare and life sciences portfolio at Andreessen Horowitz (a16z), has launched a leaner venture firm called VZVC. Shifting away from high-volume investing, the new fund focuses on a handful of concentrated bets annually while heavily integrating artificial intelligence into its operations.
In a recent discussion, Pande explored the unique intersection of AI and biology, noting that unlike text-based fields, biological data cannot simply be scraped from the web. This limitation requires companies to build proprietary datasets, fundamentally shaping the future of drug discovery and precision medicine.
- Vijay Pande left a16z after managing a $4B fund to co-found the boutique firm VZVC.
- The new firm relies on concentrated investments and day-to-day AI operations.
- Biological data cannot be web-scraped, leading to walled-off proprietary datasets.
- AI is rapidly transforming drug discovery, clinical trials, and personalized medicine.
Sources:
